Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 25:10:107.
doi: 10.1186/1475-2840-10-107.

Relation between the frequency of CD34⁺ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

Ilkay Bozdag-Turan  1 , R Goekmen Turan, C Hakan Turan, Sophie Ludovicy, Ibrahim Akin, Stephan Kische, Nicole S Arsoy, Henrik Schneider, Jasmin Ortak, Tim Rehders, Tina Hermann, Liliya Paranskaya, Peter Kohlschein, Manuela Bastian, A Tulga Ulus, Kurtulus Sahin, Hueseyin Ince, Christoph A Nienaber
Affiliations

Relation between the frequency of CD34⁺ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

Ilkay Bozdag-Turan et al. Cardiovasc Diabetol. .

Abstract

Background: Bone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease are impaired with respect to number and mobilization. However, it is unknown whether the mobilization of BM-CPCs depends on the number of diseased coronary arteries. Therefore, in our study, we analysed the correlation between the diseased coronary arteries and the frequency of CD34/45+ BM-CPCs in peripheral blood (PB) in patients with ischemic heart disease (IHD).

Methods: The frequency of CD34/45+ BM-CPCs was measured by flow cytometry in 120 patients with coronary 1 vessel (IHD1, n = 40), coronary 2 vessel (IHD2, n = 40), coronary 3 vessel disease (IHD3, n = 40) and in a control group of healthy subjects (n = 40). There was no significant difference of the total number of cardiovascular risk factors between IHD groups, beside diabetes mellitus (DM), which was significantly higher in IHD3 group compared to IHD2 and IHD1 groups.

Results: The frequency of CD34/45+ BM-CPCs was significantly reduced in patients with IHD compared to the control group (CD34/45+; p < 0.001). The frequency of BM-CPCs was impaired in patients with IHD3 compared to IHD1 (CD34/45+; p < 0.001) and to IHD2 (CD34/45+; p = 0.001). But there was no significant difference in frequency of BM-CPCs between the patients with IHD2 and IHD1 (CD34/45+; p = 0.28). In a subgroup we observed a significant negative correlation between levels of hemoglobin AIc (HbAIc) and the frequency of BM-CPCs (CD34/45+; p < 0.001, r = -0.8).

Conclusions: The frequency of CD34/45+ BM-CPCs in PB is impaired in patients with IHD. This impairment may augment with an increased number of diseased coronary arteries. Moreover, the frequency of CD34/45+ BM-CPCs in ischemic tissue is further impaired by diabetes in patients with IHD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The frequency of CD34/45+ BM-CPCs were significanty reduced a total of IHD patients as compared to healthy subjects.
Figure 2
Figure 2
The frequency of CD34/45+ BM-CPCs was impaired in patients with IHD3 as compared to IHD1. But there was no significant difference in frequency of BM-CPCs between the patients with IHD2 and IHD1.
Figure 3
Figure 3
We observed a significantly inverse correlation between the frequency of CD34/45+ BM-CPCs and levels of HbA1C in total of IHD patients with diabetes (n = 40).
Figure 4
Figure 4
The CD34/45+ BM-CPCs frequency was significanty reduced in a total of DM patients with HbA1C > 7% (n = 20) as compared to DM patients with HbA1C < 7% (n = 20).
See this image and copyright information in PMC

References

    1. Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors from biology to treatment. Trends Cardiovasc Med. 2002;12:88–96. doi: 10.1016/S1050-1738(01)00152-9. - DOI - PubMed
    1. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells, new hope for a broken heart. Circulation. 2003;107:3093–100. doi: 10.1161/01.CIR.0000074242.66719.4A. - DOI - PubMed
    1. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA. 2000;97:3422–3427. doi: 10.1073/pnas.070046397. - DOI - PMC - PubMed
    1. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:1–7. doi: 10.1161/hh1301.093825. - DOI - PubMed
    1. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Lewine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781–6. doi: 10.1161/01.CIR.0000039526.42991.93. - DOI - PubMed

MeSH terms